User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

3470

Interactions with Platform & by Email *

INTERACTIONS

625

Unique # Participated *

PARTICIPANTS

104

Responses Validated *

VALIDATIONS

30

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   Present Scenario and Outlook.....II-4
Current & Future Analysis.....II-4
Patent Expiries to Check Market Growth.....II-4
1$100
   New Drugs to Sustain Growth.....II-5
A Curtain Raiser.....II-5
Drugs Developed in the Recent Past.....II-5
1$100
   What the Future Holds in Store?.....II-6
Where Does the Opportunity Lie?.....II-6
In the Shifting Demographics .....II-6
1$100
   Which Disease Segment Offers Abundant Opportunities for R&D Initiatives.....II-71$100
   Leading Companies & Their Areas of Research Interest/Focus.....II-8
Business Opportunities in Ophthalmology: A Fact Sheet.....II-8
Impediments in Picking the Ripe & Low Hanging Opportunities.....II-8
Low Patient Compliance.....II-8
1$100
   What’s the Antidote to Low Patient Compliance?.....II-9
Innovation in Ophthalmic Pharmaceuticals: How Does It Help Patients?.....II-9
1$100
   An Unequivocal Discussion About Ocular Drug Design and Delivery.....II-10
Why Understanding of the Metabolic Activity of the Eye is Important?.....II-10
1$100
   Pitfalls of Traditional Ocular Treatment.....II-11
Ophthalmic Drug Delivery: A Recapitulation of Facts.....II-11
1$100
   Antidotes to Low Delivery of Ocular Drugs & High Side Effects.....II-121$100
   Prodrug.....II-13
Soft Drugs (SDs).....II-13
Soft Corticosteroids.....II-13
Drug Penetration Enhancers.....II-13
1$100
   Chitosan Based Drugs & Drug Delivery Systems.....II-14
How Chitosan is used to Improve Ocular Drug Retention On the Eye’s Surface?.....II-14
1$100
   The Future of Ophthalmic Drug Delivery.....II-15
A Straight Talk About Ophthalmic Drug Delivery Technologies.....II-15
High Flying Expectations of Blistering Pace of Drug Development Grounded.....II-15
1$100
   First Generation Advancements Made in Ocular Drugs.....II-16
Second Generation Advancements Made in Ocular Drugs.....II-16
1$100
   Limiting Factors.....II-171$100
   Ophthalmic Pharmaceuticals Poised to Encounter Days of Plenty.....II-18
Ophthalmic Inserts Flaunt the Potential to Eclipse the Popularity of Eye Drops.....II-18
1$100
   Rising Incidences of Glaucoma: A Business Case for Ophthalmic Drugs.....II-19
Lack of Awareness Creates Huge Burden.....II-19
1$100
   Financial Costs of Glaucoma Plague Developed and Developing Countries.....II-201$100
   Aging Population & Environmental Factors Drive Growth.....II-21
Increase in Healthcare Spending.....II-21
Opportunities Abound in the Developing Countries.....II-21
Innovative Products Lend Traction to Growth.....II-21
1$100
   Reimbursements: “Under the Umbrella”.....II-22
Pricing Statistics On Select Ophthalmic Drugs in the US (2006) – A Perspective
  Builder.....II-22
2$125
   Price Changes for Select Ophthalmic Drugs in the Year 2005.....II-241$100
   Anti Viral Drugs.....II-25
Adenoviral Infections.....II-25
Herpes Simplex Virus.....II-25
Herpes Zoster (Varicella Zoster Disease).....II-25
Corticosteroids.....II-25
1$100
   Loteprednol.....II-26
Prednisolone.....II-26
1$100
   Dexamethasone.....II-27
Fluorometholones.....II-27
Fluorometholone Alcohol.....II-27
Fluorometholone Acetate.....II-27
1$100
   Rimexolone.....II-28
Clinical Efficacy of Steroids.....II-28
Topical Corticosteroid Drugs.....II-28
1$100
   Tapering of Steroid Intake.....II-29
Non-Steroids Anti Inflammatory Drugs (NSAID).....II-29
1$100
   Use of Topical NSAIDs.....II-30
Topical & Systemic NSAIDs.....II-30
Ketorolac: A Potent NSAID.....II-30
1$100
   Non-Steroidal Anti-Inflammatory Drugs.....II-31
Antibiotics.....II-31
Sodium Sulfacetamide.....II-31
1$100
   Sulfisoxazole.....II-32
Bacitracin.....II-32
Bacitracin and Polymyxin B: A Powerful Duo.....II-32
Bacitracin, Polymyxin B and Neomycin: Three To Tango.....II-32
1$100
   Trimethoprim with Polymyxin B.....II-33
Chloramphenicol.....II-33
Erythromycin.....II-33
1$100
   Gentamicin and Tobramycin.....II-34
Fluoroquinolones.....II-34
Types of Fluoroquinolones.....II-34
Ciprofloxacin.....II-34
Gatifloxacin.....II-34
1$100
   Levofloxacin.....II-35
Moxifloxacin.....II-35
Ofloxacin.....II-35
1$100
   Topical Antibiotic Drugs.....II-36
Ophthalmic Antihistamines.....II-36
Azelastine.....II-36
Emedastine.....II-36
1$100
   Epinastine.....II-37
Ketotifen.....II-37
Olopatadine.....II-37
Ophthalmic Mast-Cell Stabilizers.....II-37
Cromolyn.....II-37
1$100
   Nedocromil Sodium.....II-38
Pemirolast.....II-38
Drugs to Treat Glaucoma.....II-38
Beta-Adrenergic Blockers or "Beta Blockers".....II-38
1$100
   Timolol.....II-39
Levobunolol.....II-39
Carteolol.....II-39
Metipranolol.....II-39
Betaxolol.....II-39
1$100
   Alpha-Adrenergic Agonists.....II-40
Carbonic Anhydrase Inhibitors.....II-40
Acetazolamide.....II-40
1$100
   Dorzolamide.....II-41
Acetazolamide & Dorzolamide: How Good Is the Combo?.....II-41
Miotics.....II-41
Prostaglandins.....II-41
1$100
   Mydriatics & Cycloplegics.....II-42
Side Effects.....II-42
Over-The-Counter (OTC) Ophthalmic Preparations.....II-42
Artificial Tears.....II-42
1$100
   Lubricating Ointments.....II-43
Mast Cell Stabilizers.....II-43
Antihistamines.....II-43
1$100
   Phenylephrine.....II-44
Naphazoline.....II-44
Xylometazoline.....II-44
Astringents.....II-44
1$100
   Over-The-Counter Ophthalmic Preparations.....II-451$100
   A Directory Listing of Major Ophthalmic Pharmaceutical Drugs.....II-46
Formulary Anti- Glaucoma Drugs.....II-46
1$100
   Non-Formulary Anti- Glaucoma Drugs.....II-47
Formulary Topical Anti-Glaucoma Drugs.....II-47
1$100
   Formulary Ophthalmic Antiinfective/Corticosteroids Drugs.....II-48
Non-Formulary Ophthalmic Antiinfective/ Corticosteroids Drugs.....II-48
1$100
   Formulary Ophthalmic Corticosteroid Drugs.....II-49
Non-Formulary Ophthalmic Corticosteroid Drugs.....II-49
1$100
   Formulary Ophthalmic Topical Antibacterial Drugs.....II-501$100
   Non-Formulary Ophthalmic Topical Antibacterial Drugs.....II-51
Formulary Ophthalmic Topical Antiviral Drugs.....II-51
Other Ophthalmic Formulary Drugs.....II-51
1$100
   Other Ophthalmic Non-Formulary Drugs.....II-522$125
   Pipeline Drugs.....II-541$100
   The Human Eye: A Remarkable & Intriguing Organ of Sight.....II-55
The Outer Layer.....II-55
The Middle Layer.....II-55
1$100
   The Inner Layer.....II-56
Common Ophthalmic Disorders: An Exposition.....II-56
Cataract.....II-56
Causes.....II-56
1$100
   Types of Cataract.....II-57
Treatment Strategies.....II-57
1$100
   How Widespread is the Disease?.....II-58
Glaucoma.....II-58
Who’s At Risk?.....II-58
1$100
   Types of Glaucoma.....II-59
Primary Open Angle Glaucoma (POAG).....II-59
Acute Angle-Closure Glaucoma (AACG).....II-59
Congenital Glaucoma.....II-59
Secondary Glaucoma.....II-59
1$100
   Treatment Strategies.....II-60
Anti- Glaucoma Ophthalmic Drugs.....II-60
1$100
   Table 1: Global Market for Glaucoma Pharmaceuticals (2008): Percentage Value Share Breakdown of Leading Players - Pfizer Inc., Allergan Inc., Merck & Co., Alcon, Ista Pharmaceuticals, and Others (includes corresponding Graph/Chart).....II-611$350
   Table 2: Leading Glaucoma Pharmaceutical Products in the Global Market (Excluding US) (2008, 2010 & 2012): Percentage Breakdown of Value Sales for Xalatan/ Xalcom, Cosopt/ Trusopt, Travatan/ Extravan, Lumigan/Ganfort, Alphagan/Combigan, Timoptic/ XE, Generic Timolol and Others (includes corresponding Graph/Chart).....II-62
How Widespread is the Disease?.....II-62
1$350
   Table 3: Prevalence of Glaucoma in the World: Year 1999 and 2006 A Comparison (In 000 Individuals) (includes corresponding Graph/Chart).....II-631$350
   Is Marijuana A Potential Cure?.....II-64
Age-Related Macular Degeneration (AMD).....II-64
Types of AMD.....II-64
Dry AMD (Non-Neovascular).....II-64
Wet AMD (Neovascular).....II-64
1$100
   Causes.....II-65
Treatment Strategies.....II-65
1$100
   Nutrition & AMD.....II-66
Diabetic Retinopathy.....II-66
How Widespread is the Disease?.....II-66
1$100
   Table 4: Diabetic Retinopathy Patient Prevalence in the US by Diabetes Type: 2006-2015 (In Thousand Patients) (includes corresponding Graph/Chart).....II-67

Table 5: Diabetic Retinopathy Patient Prevalence in the US by Age Group: 2006-2012 (includes corresponding Graph/Chart).....II-67
1$350
   Table 6: Diabetic Retinopathy Prevalence in Type-1 Diabetic Patients in the US by Age Group: 2006-2012 (includes corresponding Graph/Chart).....II-68
Treatment Strategies.....II-68
1$350
   Market Awaits First Approved Drug; Off-label Use Continues.....II-69
Diabetic Retinopathy Drug Market to Post Dramatic Growth.....II-69
1$100
   Select Pipeline Drugs in Diabetic Retinopathy Market.....II-70
Additional Trials Delay Arxxant’s Launch.....II-70
1$100
   Lucentis Shows Promise in Diabetic Retinopathy Treatment.....II-71
Pycnogenol Continues to Appeal to Researchers.....II-71
1$100
   Robo4 Protein – A Potential Therapeutic for Diabetic Retinopathy.....II-72
Bevacizumab Bodes Potential As An Adjunct to Surgery PDR Treatment.....II-72
1$100
   Ocular Allergies.....II-73
Treatment Strategies.....II-73
1$100
   Immunotherapy: A Popular Anti-Allergy Treatment Approach.....II-74
Ocular Inflammation: A Symptom of Ocular Allergies.....II-74
1$100
   How Can Allergies Be Prevented?.....II-75
Conjunctivitis (Pink Eye).....II-75
1$100
   Types of Conjunctivitis.....II-76
Pathogenesis.....II-76
Treatment Strategies.....II-76
1$100
   Keratitis.....II-77
Types of Keratitis.....II-77
1$100
   Treatment Strategies.....II-78
Dry Eye.....II-78
1$100
   Why Are Tears So Crucial for Normal Eye Health?.....II-79
What Causes Dry Eye?.....II-79
Treatment Strategies.....II-79
1$100
   Refractive Errors.....II-80
Causes for Refractive error.....II-80
Treatment for Refractive Errors.....II-80
Cost of Treatment.....II-80
1$100
   Factors contributing to the Difference in Surgery Costs.....II-811$100
   Zymaxid Obtains US FDA Approval.....II-82
Carco Introduces Azelastine Ophthalmic Solution, 0.05%.....II-82
Fera Pharmaceuticals Launches Neptazane Tablets.....II-82
Banyu Pharmaceutical Introduces Cosopt Combinational Ophthalmic Solution.....II-82
Bausch & Lomb Launches Soothe Xtra Hydration Eye Drops in the US.....II-82
1$100
   Akorn Secures FDA Clearance for Erythromycin Ophthalmic Ointment.....II-83
Teva Launches New Dorzolamide Hydrochloride Ophthalmic Solution.....II-83
Caraco Pharmaceutical Laboratories Introduces New Ophthalmic Drug.....II-83
Auxano Diagnostics Introduces Novel Point-of-Care Indicator System.....II-83
Senju Pharmaceutical to Launch LUMIGAN® Ophthalmic Solution in Japan.....II-83
1$100
   Sirion Receives FDA Approval for Zirgan.....II-84
ISTA Pharmaceuticals Obtains FDA Approval for BepreveTM.....II-84
Aton Pharma Reintroduces TIMOPTIC® in OCUDOSE®.....II-84
Novagali Pharma Obtains FDA Clearance for Phase III Study for Catioprost.....II-84
1$100
   Allergen Obtains FDA Approval for New Ophthalmic Product.....II-85
Akorn Receives FDA Approval for Ciprofloxacin HCl Ophthalmic Solution USP.....II-85
Akorn Introduces Akten Gel.....II-85
Sirion Launches Topical Ophthalmic Drug.....II-85
FDC Obtains FDA Approval for Ciprofloxacin Ophthalmic Solution.....II-85
Novagali Pharma to Introduce Cationorm® in France.....II-85
Allergan Obtains FDA Clearance for Combigan.....II-85
1$100
   Novagali Obtains FDA Approval of Nova22007 IND for Ph III Trial.....II-86
Alimera Conducts Phase III Medidur Trial.....II-86
ISTA Pharmaceuticals Files NDA for Xibrom™ QD.....II-86
AzaSite Receives FDA Approval.....II-86
1$100
   Inspire Pharmaceuticals Rolls Out AzaSite™ for Ocular Infections.....II-87
Alimera Sciences Receives FDA Approval.....II-87
Alcon Receives Approval for Vegamox™ Ophthalmic Solution in Japan.....II-87
Alcon Receives Marketing Approval for Patanol® in Japan.....II-87
1$100
   Allergan Receives FDA Approval for Lumigan®.....II-88
Allergan’s Ganfort® Receives Pan European License.....II-88
Pfizer Receives Approval from EC to Market Macugen®.....II-88
Akorn Gets Nod for Conducting Clinical Trial of AK-1015.....II-88
Genentech ‘s Lucentis Receives FDA Approval.....II-88
MacuSight Receives FDA Approval for IND Application of Sirolimus.....II-88
1$100
   Sami Labs Receives Approval for Ocufors.....II-89
Toyamo and Nidek Obtain Manufacturing Approval for Quinolone Ophthalmic
  Solutions.....II-89
Reckitt Benckiser Launches Two Eye Care Products.....II-89
Alcon Launches DUOTRAV for Glaucoma Treatment.....II-89
Macugen® Receives European Regulatory Approval.....II-89
Rohto Pharmaceutical Launches Switch OTC Ophthalmic Drug.....II-89
1$100
   Indoco Remedies to Launch Ophthalmic Drugs in America.....II-90
Alcon's NEVANAC Receives FDA Approval.....II-90
Fougera Obtains Approval for MetroGel®.....II-90
Allergan’s Alphagan P Receives FDA Approval.....II-90
Santen Obtains Approval for Manufacturing and Marketing PAPILOCK.....II-90
Akorn Launches Ophthalmic Drug Products.....II-90
1$100
   AlphaRx Formulates the Ophthalmic Product, Binoxan™.....II-91
Alimera Sciences Introduces Online Consumer Ordering Facility.....II-91
Fougera Adds Two Novel Products to its Ophthalmic Product Line.....II-91
Micro Vision Launches Anti-Glaucoma Drugs.....II-91
Alcon Receives FDA Approval for Adding Susceptible Pathogens to VIGAMOX.....II-91
BOL Receives FDA Approval for Ofloxacin.....II-91
Hi-Tech Pharmacal Receives FDA Clearance for Ofloxacin Ophthalmic Solution.....II-91
1$100
   Vision Blue and DORC International Receives FDA Approval for Trypan Blue.....II-92
Pfizer Receives FDA Nod for Macugen®.....II-92
Bausch & Lomb Bags FDA Approval for its Zylet™.....II-92
ISTA Pharmaceuticals Launches Istalol for Glaucoma Treatment in the US.....II-92
Falcon Unveils Trifluridine Ophthalmic Solution, 1%.....II-92
Alimera Sciences Unveils Soothe™ Emollient Eye Drops.....II-92
1$100
   Novartis Introduces Zaditen in Japan.....II-93
Falcon Releases Brimonidine Tartrate Ophthalmic Solution, 0.2%.....II-93
Alcon Receives Approval for Olopatadine (Patanol).....II-93
Pharmacia Receives FDA Approval for Latanoprost Ophthalmic Solution.....II-93
US FDA Approves Allergan’s New Acular LS 0.4% for Ocular Pain Reduction.....II-93
Allergan Obtains FDA Approval for Zymar.....II-93
1$100
   Taiwanese Researchers Introduces Thermosensitive Ophthalmic Drop.....II-94
Alcon Introduces Systane Lubricant Eye Drops.....II-94
Allergan Releases Restasis for Dry Eye Treatment.....II-94
Biosyntrx Launches BioTears.....II-94
Novartis to Introduce Pirenzepine Ophthalmic Gel.....II-94
1$100
   Bausch & Lomb Takes Over Zirgan®.....II-95
Inspire and Santen Secure Japanese Approval for DIQUAS.....II-95
Asahi Kasei Pharma and Altheos Enter into License Agreement.....II-95
OPKO Health Takes Over Pharmacos Exakta.....II-95
1$100
   Alcon Acquires Rights of Two Ophthalmic Pharmaceutical Products of Sirion.....II-96
QLT Secures Rights from Othera Pharmaceuticals.....II-96
Novartis Acquires 77% Stake in Alcon.....II-96
Pfizer Acquires Wyeth.....II-96
1$100
   Pieris Collaborates With Allergan to Treat Ocular Disorders.....II-97
Bausch & Lomb Takes Over Commercial Assets of Tubilux.....II-97
I-Therapeutix Changes Its Name to Ocular Therapeutix.....II-97
Alcon Signs Collaborative Research Agreement with AstraZeneca.....II-97
Fera Pharmaceuticals Takes Over Seven Ophthalmic Ointments of Fougera.....II-97
1$100
   Bausch & Lomb Obtains Approval for Novel Ophthalmic Product.....II-98
Alcon to Set Up Manufacturing Facility in Singapore.....II-98
Inspire Pharmaceuticals Selects Clinipace to Conduct Phase II Clinical Trials.....II-98
Regeneron and Bayer to Extend Global Development Collaboration.....II-98
1$100
   Sucampo Obtains Rights to Commercialize Rescula.....II-99
Santen and Merck Inks Licensing Agreement.....II-99
InSite Vision Inks Licensing and Distribution Agreement with Nitten.....II-99
1$100
   OPKO Terminates Phase III Trial of Bevasiranib.....II-100
Sirion Therapeutics Signs Agreement with Advanced Vision Research.....II-100
Bausch & Lomb and Pfizer Ink Co-Promotion Agreement.....II-100
NanoViricides Inks Material Transfer Agreement for Ophthalmic Antiviral.....II-100
1$100
   MacuCLEAR Partners with Mystic for Clinical Trials.....II-101
Sohm Inks Private Label and Development Agreement with Indian Company.....II-101
Adeona Forms Research Collaboration with NNRI.....II-101
1$100
   Santen Receives Approval for TAPROS from MHLW.....II-102
Otsuka and Acucela Ink Definitive Co-Development Deal for Rebamipide.....II-102
Canadian Bio Med Systems Obtains Licensing Rights for Two Ophthalmic Products.....II-102
Novartis Acquires Minority Stake in Alcon from Nestle.....II-102
OPKO Acquires Development and Commercialization Rights to Doxovir™.....II-102
1$100
   InSite Vision Inks Licensing and Distribution Agreement with Essex.....II-103
arGentis Pharmaceuticals Obtains License for New Ophthalmic Drug.....II-103
Opko Health Finalizes Vidus Ocular Take Over.....II-103
InSite Vision Inks Licensing and Distribution Agreement with Biem.....II-103
Bausch & Lomb Inks Collaborative Research Agreement with Galapagos.....II-103
1$100
   PRP and Jerini Ink License and Development Agreement with Jerini Ophthalmic.....II-104
Akorn Inks Manufacturing and Supply Agreement with a US Company.....II-104
Sirion and Bridge Pharma Sign Licensing Agreement.....II-104
NicOx Extends Collaboration Agreement with Pfizer.....II-104
Bausch & Lomb Acquires IOL Maker, Eyeonics.....II-104
1$100
   Akorn Inks Manufacture &Supply Agreement for Ophthalmic Solution.....II-105
CrystalGenomics Enters Into R&D Agreement with Bausch & Lomb.....II-105
1$100
   Genaera Corporation Quits Evizon Clinical Trials.....II-106
Eyetech Inc Divests Anti-Platelet Derived Growth Factor (PDGF) Aptamer
  Program.....II-106
Amneal, Indoco Agree to Develop & Market Generic Ophthalmic Drugs.....II-106
Bausch & Lomb Acquire Soothe Products from Alimera.....II-106
Froptix, Acuity, eXegenics Merge to Form Opko Corporation.....II-106
1$100
   Alimera, Emory Collaborate Over Potential Ophthalmic Treatments Using Novel
  Antioxidants.....II-107
Santen Signs Agreement with Vistakon Pharmaceuticals for US Launch of Iquix®.....II-107
Inspire Pharmaceuticals Rolls Out AzaSite™ for Ocular Infections.....II-107
QLT Takes Over Forsight Newco II, Inc.....II-107
Phase IV Clinical Trials Of Macugen®.....II-107
1$100
   Results Of Phase II Clinical Trials – Macugen®.....II-108
Bausch & Lomb Purchases OTC Allergy Drugs of Alimera.....II-108
Phase II Trial of Acuity Pharmaceutical’s Bevasiranib.....II-108
Advanced Refractive Technologies Acquires a Subsidiary of UTEK Corporation.....II-108
1$100
   Sirion Therapeutics Acquires Sytera.....II-109
Teva Pharmaceuticals Acquires Ivax.....II-109
Alcon Enters into an Agreement with Amgen.....II-109
QLT Signs an Agreement with Retinagenix.....II-109
NicOx Enters into Licensing Agreement with Pfizer.....II-109
OccuLogix Signs Agreement to Acquire SOLX.....II-109
1$100
   ISTA Receives License from Senju for Allergy Treatments.....II-110
Acuity Receives License for Nchlorotaurine.....II-110
Akorn and AVR Enter into Commercial Manufacturing & Supply Agreement.....II-110
Lantibio Signs Agreement with TRB Chemedica.....II-110
Argentis and Southern College of Optometry Enter into Agreement.....II-110
Bausch & Lomb Enters into Marketing Agreement with Novartis.....II-110
Santen Pharmaceuticals and Ube Industries to Develop Glaucoma Therapy Jointly.....II-110
1$100
   Santen Pharmaceutical and CytoPathfinder Signs an Agreement.....II-111
Kalypsys Inks an Agreement with Alcon, Inc.....II-111
Combination RX Enters into a Collaboration Agreement with Fovea.....II-111
Par Pharmaceutical Joins Force with Spectrum Pharmaceuticals.....II-111
Isotechnika Sells Eye Drug Rights to Lux Biosciences.....II-111
Alimera Sciences Collaborates With CYNACON.....II-111
1$100
   Novartis Inks an In-Licensing Agreement with Otsuka.....II-112
Alimera Sciences Commences Phase III Trials for Medidur™.....II-112
SurModics Acquires InnoRx.....II-112
Bausch & Lomb Acquires Shandong Chia Tai Freda Pharmaceutical Group.....II-112
OSI Pharmaceuticals Takes Over Eyetech Pharmaceuticals.....II-112
1$100
   Pfizer Acquires Angiosyn.....II-113
Bausch & Lomb Collaborates with PTC Therapeutics.....II-113
AMRI Enters into Research Collaboration with Alcon.....II-113
Bausch & Lomb Bags License from Cephalon.....II-113
PediaMed and Allergan Sign a Co-Promotion Agreement.....II-113
SurModics Bags Option to Acquire Exclusive Rights from Rutgers University.....II-113
1$100
   Sankyo Co. and Santen Pharmaceutical Sign Agreement.....II-114
Acuity Pharmaceuticals Enters into Agreement with Intradigm Corporation.....II-114
Apotex Inks Marketing Agreement with Akorn.....II-114
Novartis Enters into an Agreement with Senju Pharmaceutical.....II-114
Novartis Strikes a Licensing Deal with Otsuka Pharmaceutical.....II-114
Custom RX recalls Trypan Blue 0.06% Ophthalmic Solution.....II-114
AMO Takes Over VISX.....II-114
Advanced Medical Optics Acquires Ophthalmic Surgical Business of Pfizer.....II-114
1$100
   Santen to Take Over Marketing Rights of Rescula from R-Tech Ueno.....II-115
Alimera Sciences Inks Co-promotion Agreement with VISTAKON Pharmaceuticals.....II-115
Akorn Inks a Purchase and Supply Agreement with FDC.....II-115
ISTA Pharmaceuticals Receives Marketing License From Senju Pharmaceuticals.....II-115
Pfizer Inc Acquires Pharmacia Corp.....II-115
Allergan Takes Over Oculex Pharmaceuticals.....II-115
Allergan Enters into an Agreement with Acadia.....II-115
1$100
   Akorn, Inc. (USA).....II-116
Alcon, Inc. (Switzerland).....II-116
1$100
   Allergan, Inc. (USA).....II-1171$100
   Alimera Sciences, Inc. (USA).....II-118
Bausch & Lomb, Inc. (USA).....II-118
1$100
   Genvec, Inc. (USA).....II-119
Glaxosmithkline Plc. (UK).....II-119
Inspire Pharmaceuticals, Inc. (USA).....II-119
ISTA Pharmaceuticals, Inc. (USA).....II-119
1$100
   Merck & Co., Inc. (USA).....II-120
Novartis Ophthalmics (Canada).....II-120
Opko Health, Inc. (USA).....II-120
Otsuka Pharmaceutical Co., Ltd. (Japan).....II-120
1$100
   Pfizer, Inc. (USA).....II-121
QLT, Inc. (Canada).....II-121
Santen Pharmaceutical Co. (Japan).....II-121
1$100
   Santen Inc. (US).....II-1221$100
   Table 7: World Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-1231$350
   Table 8: World Historic Review for Ophthalmic Pharmaceutical Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1241$350
   Table 9: World 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart).....II-1251$350
   Table 10: World Recent Past, Current and Future Analysis for Glaucoma Treatment Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-1261$350
   Table 11: World Historic Review for Glaucoma Treatment Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1271$350
   Table 12: World 11-Year Perspective for Glaucoma Treatment Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart).....II-1281$350
   Table 13: World Recent Past, Current and Future Analysis for Ophthalmic Anti-allergy Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-1291$350
   Table 14: World Historic Review for Ophthalmic Anti-allergy Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1301$350
   Table 15: World 11-Year Perspective for Ophthalmic Anti-allergy Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart).....II-1311$350
   Table 16: World Recent Past, Current and Future Analysis for Ophthalmic Anti-infective Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-1321$350
   Table 17: World Historic Review for Ophthalmic Anti-infective Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1331$350
   Table 18: World 11-Year Perspective for Ophthalmic Anti-infective Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart).....II-1341$350
   Table 19: World Recent Past, Current and Future Analysis for Dry Eye Treatment Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-1351$350
   Table 20: World Historic Review for Dry Eye Treatment Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1361$350
   Table 21: World 11-Year Perspective for Dry Eye Treatment Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart).....II-1371$350
   Table 22: World Recent Past, Current and Future Analysis for Ophthalmic Anti-inflammatory Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-1381$350
   Table 23: World Historic Review for Ophthalmic Anti-inflammatory Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2007 (includes corresponding Graph/Chart).....II-1391$350
   Table 24: World 11-Year Perspective for Ophthalmic Anti-inflammatory Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart).....II-1401$350
   Table 25: World Recent Past, Current and Future Analysis for Back of Eye Treatment Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-1411$350
   Table 26: World Historic Review for Back of Eye Treatment Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1421$350
   Table 27: World 11-Year Perspective for Back of Eye Treatment Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart).....II-1431$350
   Table 28: World Recent Past, Current and Future Analysis for Other Ophthalmic Treatment Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-1441$350
   Table 29: World Historic Review for Other Ophthalmic Treatment Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1451$350
   Table 30: World 11-Year Perspective for Other Ophthalmic Treatment Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1461$350
   A. Market Analysis.....II-147
Outlook.....II-147
Recession Relights Sales of OTC Drugs in Pharmaceutical Industry.....II-147
Emphasis on Greater Awareness About Ophthalmic Disorders.....II-147
1$100
   Growth Drivers In a Capsule.....II-148
Impediments to Growth.....II-148
Market Fact Sheet.....II-148
1$100
   Glaucoma Market: A Primer.....II-149
Patent Expiries of Key Glaucoma Drugs.....II-149
Awareness Among Patients.....II-149
High Costs.....II-149
1$100
   Treatment Patterns Adopted By Doctors.....II-150
The All Consuming Issue of Compliance.....II-150
Drug Brands & Their Patient Compliance Score.....II-150
1$100
   Market Share Statistics.....II-151
Table 31: The US Market for Ophthalmic Pharmaceutical Drugs (2004-2007): Percentage Market Share Breakdown of Leading Players - Alcon Laboratories, Allergan, Novartis Pharmaceutical, Pfizer/OSI Pharmaceuticals, Bausch & Lomb Pharmaceuticals, and Others (includes corresponding Graph/Chart).....II-151
1$350
   Table 32: The US Market for Glaucoma Pharmaceutical Products by Leading Drugs (2008 & 2009): Market Share Breakdown in terms of Prescription Volume for Xalatan, Lumigan, Alphagan P, Travatan and Others (includes corresponding Graph/Chart).....II-1521$350
   Table 33: Leading Glaucoma Pharmaceutical Products in the US (2008, 2010 & 2012): Percentage Breakdown of Value Sales for Xalatan/Xalcom, Cosopt, Lumigan, Travatan, Alphagan, Combigan, Generic Timolol and Others (includes corresponding Graph/Chart).....II-153
Select Glaucoma Pharmaceuticals Presently Approved/ In Pipeline.....II-153
1$350
   Table 34: Top 10 Brands of Eye/Lens Care in the US: Breakdown of Dollar and Unit Sales Through Drug Stores, Supermarkets and Discount Stores For the Year Ended November 2007 (In US$ 000 and Thousand Units) (includes corresponding Graph/Chart).....II-1541$350
   Table 35: Top 5 Eye Care Products in the US: Breakdown of Dollar Sales Through Food, Drug and Mass Market Channels for the Year Ended July 2007 (In US$ Million) (includes corresponding Graph/Chart).....II-155

Table 36: Age-Related Wet Macular Degeneration Market in the United States (2004-2006): Percentage Market Share Breakdown of Leading Players - QLT Inc/Novartis Pharmaceutical Corp, and Eyetech Pharmaceuticals (OSI) / Pfizer. (includes corresponding Graph/Chart).....II-155
1$350
   Table 37: Ocular Allergy Market in the United States (2004-2007): Percentage Market Share Breakdown of Leading Players - Alcon Laboratories, Novartis Pharmaceutical, Bausch & Lomb Pharmaceuticals, Allergan, Santen, and Others (includes corresponding Graph/Chart).....II-1561$350
   Table 38: Ocular NSAIDs (Topical Non-Steroidal Anti-Inflammatory Drugs) Market in the United States (2007): Percentage Market Share Breakdown of Leading Players - Allergan, Inc. Novartis Pharmaceutical Corp., Alcon Laboratories, Inc., and ISTA Pharmaceuticals (includes corresponding Graph/Chart).....II-157

Table 39: Age-Related Macular Degeneration Market in the United States (2006): Dollar Sales of Major Branded Drugs - Visudyne, Macugen, and Lucentis (In US$ Million) (includes corresponding Graph/Chart).....II-157
1$350
   Major Anti-Glaucoma Drugs Available in the United States: Year 2006.....II-158
Major Drugs Available in the United States for the Treatment of AMD: Year
  2005.....II-158
1$100
   Drugs in the Pipeline for the Treatment of AMD in the United States: Year
  2005.....II-159
Major Drugs Available in the United States for the Control of Dry Eye: Year
  2005.....II-159
1$100
   US Market for Dry Eye: Drugs in the Pipeline Year 2005.....II-160
Companies Actively Involved in Manufacturing Drugs for Dry Eye: Year 2005.....II-160
Major Drugs Available in the United States for the Treatment of Ocular Allergies:
  Year 2005.....II-160
1$100
   US Market for Ocular Allergies: Drugs in the Pipeline: Year 2005.....II-161
Statistical Findings On Ophthalmic Diseases in the United States.....II-161
Table 40: Prevalence of Age-Related Macular Degeneration: Percentage Breakdown by Wet AMD & Intermediate Dry AMD by Age Group for the Year 2005 (includes corresponding Graph/Chart).....II-161
1$350
   Table 41: Prevalence of Age-Related Wet Macular Degeneration in the United States for the Years 2006, 2009, & 2012 (In Millions of Individuals) (includes corresponding Graph/Chart).....II-162

Table 42: Number of Individuals Treated for Wet AMD in the United States (In Thousands) for the Years 2006, 2009 & 2015 (includes corresponding Graph/Chart).....II-162

Table 43: Prevalence of Ocular Hypertension (OHT) in the United States for the Years 2006, 2009, & 2011 (In Millions of Individuals) (includes corresponding Graph/Chart).....II-162
1$350
   Table 44: Prevalence of Primary Open Angle Glaucoma (POAG) in the United States for the Years 2006, 2009, & 2011 (In Millions of Individuals) (includes corresponding Graph/Chart).....II-163

Table 45: Prevalence of Normal Tension Glaucoma (NTG) in the United States for the Years 2006, 2009, & 2011 (In Thousand Individuals) (includes corresponding Graph/Chart).....II-163

Table 46: Prevalence of Exfoliative Glaucoma (EG) in the United States for the Years 2006, 2009, & 2011 (In Thousand Individuals) (includes corresponding Graph/Chart).....II-163
1$350
   Table 47: Prevalence of Pigmentary Glaucoma (PG) in the United States for the Years 2006, 2009, & 2011 (In Thousand Individuals) (includes corresponding Graph/Chart).....II-164

Table 48: Number of Individuals Treated for Glaucoma in the United Sates (2006, 2009 and 2011): Breakdown by Type - Ocular Hypertension (OHT), Primary Open Angle Glaucoma (POAG), Normal Tension Glaucoma (NTG), Pigmentary Glaucoma (PG) and Exfoliative Glaucoma (EG) (In 000 Individuals) (includes corresponding Graph/Chart).....II-164
1$350
   Table 49: Prevalence of Ocular Allergy in the United States for the Years 2006, 2009, & 2012 (In Millions of Individuals) (includes corresponding Graph/Chart).....II-165

Table 50: Number of Individuals Treated for Ocular Allergy in the United States (In Million) for the Years 2006, 2009 & 2012 (includes corresponding Graph/Chart).....II-165

Table 51: Prevalence of Cataract in the United States: Percentage Breakdown by Age Group for the Year 2005 (includes corresponding Graph/Chart).....II-165
1$350
   Table 52: Prevalence of Cataract in the United States for the Years 2006, 2009, & 2012 (In Millions of Individuals) (includes corresponding Graph/Chart).....II-166

Table 53: Number of Individuals Treated for Cataract With Ocular NSAIDs (Topical Non-Steroidal Anti-Inflammatory Drugs) in the United States for the Years 2006, 2009 & 2012 ((In Millions) (includes corresponding Graph/Chart).....II-166

Table 54: Prevalence of Dry Eye in the United States for the Years 2006, 2009, & 2012 (In Millions of Individuals) (includes corresponding Graph/Chart).....II-166

Table 55: Number of Individuals Treated for Dry Eye in the United States (In 000s) for the Years 2006, 2009 & 2012 (includes corresponding Graph/Chart).....II-166
1$350
   B. Market Analytics.....II-167
Table 56: US Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-167
1$350
   Table 57: US Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1681$350
   Table 58: US 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1691$350
   A. Market Analysis.....II-170
Outlook.....II-170
Lack of Awareness: A Key Issue.....II-170
1$100
   B. Market Analytics.....II-171
Table 59: Canadian Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-171
1$350
   Table 60: Canadian Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1721$350
   Table 61: Canadian 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others for Years 2005, 2010 and 2015 (includes corresponding Graph/Chart).....II-1731$350
   A. Market Analysis.....II-174
Outlook.....II-174
Growth Drivers.....II-174
Market Data Statistics.....II-174
Leading Ophthalmic Pharmaceutical Brands In the Market.....II-174
1$100
   Table 62: Japanese Market for Prescription Ophthalmic Drugs: Percentage Breakdown by Therapeutic Area - Glaucoma, Infection, Corneal Disorder, Ocular Allergy, Surgical Preparation, Steroid, Cataract, and Others. (includes corresponding Graph/Chart).....II-1751$350
   B. Market Analytics.....II-176
Table 63: Japanese Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-176
1$350
   Table 64: Japanese Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1771$350
   Table 65: Japanese 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1781$350
   A. Market Analysis.....II-179
Outlook.....II-179
A Market Primer.....II-179
Drug Reimbursement in Europe.....II-179
2$125
   B. Market Analytics.....II-181
Table 66: European Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Country/ Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-181
1$350
   Table 67: European Historic Review for Ophthalmic Pharmaceutical Drugs by Country/Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1821$350
   Table 68: European 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Country/ Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2005, 2010, and 2015 (includes corresponding Graph/Chart).....II-1831$350
   Table 69: European Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti- inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-1841$350
   Table 70: European Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Others Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1851$350
   Table 71: European 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1861$350
   A. Market Analysis.....II-187
Outlook.....II-187
1$100
   B. Market Analytics.....II-188
Table 72: French Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti- inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-188
1$350
   Table 73: French Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1891$350
   Table 74: French 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1901$350
   Market Analysis.....II-191
Market Analysis.....II-191
1$100
   Table 75: German Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-1921$350
   Table 76: German Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1931$350
   Table 77: German 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1941$350
   Market Analysis.....II-195
Market Analysis.....II-195
1$100
   Table 78: Italian Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-1961$350
   Table 79: Italian Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-1971$350
   Table 80: Italian 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-1981$350
   A. Market Analysis.....II-199
Outlook.....II-199
1$100
   B. Market Analytics.....II-200
Table 81: UK Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-200
1$350
   Table 82: UK Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-2011$350
   Table 83: UK 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-2021$350
   A. Market Analysis.....II-203
Outlook.....II-203
How & Why the Health Insurance System in Spain is Conducive?.....II-203
Pharmaceutical Reimbursement Reforms in Spain (1996-2002).....II-203
2$125
   B. Market Analytics.....II-205
Table 84: Spanish Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-205
1$350
   Table 85: Spanish Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-2061$350
   Table 86: Spanish 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-2071$350
   A. Market Analysis.....II-208
Outlook.....II-208
1$100
   B. Market Analytics.....II-209
Table 87: Rest of Europe Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-209
1$350
   Table 88: Rest of Europe Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-2101$350
   Table 89: Rest of Europe 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-2111$350
   A. Market Analysis.....II-212
Outlook.....II-212
1$100
   B. Market Analytics.....II-213
Table 90: Asia-Pacific Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-213
1$350
   Table 91: Asia-Pacific Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-2141$350
   Table 92: Asia-Pacific 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-2151$350
   Market Analysis.....II-216
Market Analysis.....II-216
1$100
   Table 93: Latin American Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-2171$350
   Table 94: Latin America Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-2181$350
   Table 95: Latin American 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-2191$350
   A. Market Analysis.....II-220
Outlook.....II-220
1$100
   B. Market Analytics.....II-221
Table 96: Rest of World Recent Past, Current and Future Analysis for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-221
1$350
   Table 97: Rest of World Historic Review for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....II-2221$350
   Table 98: Rest of World 11-Year Perspective for Ophthalmic Pharmaceutical Drugs by Therapeutic Category - Percentage Breakdown of Dollar Sales for Glaucoma, Anti-allergy, Anti-infective, Dry Eye, Anti-inflammation, Back of Eye and Other Therapeutic Categories Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart).....II-2231$350
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com